Aurinia Pharmaceuticals Inc (AUPH)
NASDAQ: AUPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
AUPH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.13B
- P/E (TTM)
- 7.02
- Forward P/E
- 15.01
- EPS (TTM)
- $2.28
- Dividend yield
- None
- 52-week range
- 10.90 – 19.25
- Day range
- 15.50 – 16.15
- Volume / Avg
- 682.53K / 1.01M
- Beta
- —
- Shares outstanding
- 133.05M
- Next earnings
- Nov 3, 2026
52-week range
AUPH stock today
Aurinia Pharmaceuticals (AUPH) closed at $16.01 on Oct 7, up 2.04% (+$0.32), versus the S&P 500's 0.22% decline. At this level, AUPH sits in the middle of its 52-week range of $10.90 to $19.25: 16.8% below the high, set on Jun 24, 2026 and 46.9% above the low. AUPH is up 0.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 36.7%.
Aurinia Pharmaceuticals trades at 7.0x its trailing twelve-month earnings per share of $2.28. Its forward P/E of 15.0x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year. Aurinia Pharmaceuticals's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Aurinia Pharmaceuticals
Company profileAurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Kevin C. Tang
- Headquarters
- Edmonton, AB
- Employees
- 128
- Website
- auriniapharma.com
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$17.86+11.56%
- Strong buy 0
- Buy 0
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $0.21
Aurinia Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VERAVera Therapeutics Inc. Class A | 30.25 | +2.82% | $2.18B | vs AUPH |
| VRDNViridian Therapeutics Inc. | 18.28 | +0.33% | $2.07B | vs AUPH |
| SDGRSchrodinger Inc. | 27.29 | -5.57% | $2.04B | vs AUPH |
| PHVSPharvaris N.V. | 31.68 | +1.80% | $2.22B | vs AUPH |
| PRGOPerrigo Company plc | 14.55 | +3.93% | $2.01B | vs AUPH |
| IMNMImmunome Inc. | 19.10 | -1.11% | $2.25B | vs AUPH |
| PBHPrestige Consumer Healthcare Inc. | 47.57 | +2.43% | $2.25B | vs AUPH |
| URGNUroGen Pharma Ltd. | 40.70 | -1.76% | $1.99B | vs AUPH |
Indexes, lists and sector
Aurinia Pharmaceuticals stock FAQ
What is Aurinia Pharmaceuticals's stock price today?
AUPH last traded at $16.01 as of Oct 7, 4:00 PM EDT, up 2.04% on the day. Prices are delayed at least 15 minutes.
When is Aurinia Pharmaceuticals's next earnings date?
Aurinia Pharmaceuticals is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $0.21.
What is AUPH's P/E ratio?
AUPH trades at a trailing P/E ratio of 7.02 and a forward P/E of 15.01.
Who is Aurinia Pharmaceuticals's CEO?
Mr. Kevin C. Tang is the chief executive officer of Aurinia Pharmaceuticals Inc, which has about 128 employees.
What is the AUPH 52-week high?
The 52-week high for AUPH is $19.25 and the 52-week low is $10.90. The stock is currently 16.8% below its high.